MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments. The company also provides life science products and services for use in the discovery, development, and manufacture of drug therapies, as well as in laboratories; and specialty chemicals for use in displays, computer chips, surfaces, Integrated circuits, microelectronic systems, anti-reflection coatings, and cosmetics. It has alliances with Pfizer Inc., Bristol-Myers Squibb Company, Intrexon Corporation, Avillion LLP., F-star Delta Ltd, SFJ Pharmaceuticals Group, Alibaba Health, Checkmate Pharmaceuticals, Solvias, and Leap Therapeutics, Inc., as well as a collaboration with Daiichi Sankyo Company, Limited. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.
Industry, Sector and Symbol
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone49 6151 72 0
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$15.35 billion
Profitability
Miscellaneous
Employees51,039
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Merck KGaA (ETR:MRK) Frequently Asked Questions
What is Merck KGaA's stock symbol?
Merck KGaA trades on the ETR under the ticker symbol "MRK."
When is Merck KGaA's next earnings date?
Has Merck KGaA been receiving favorable news coverage?
News coverage about MRK stock has been trending somewhat negative on Monday, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Merck KGaA earned a news impact score of -1.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Merck KGaA.
Who are some of Merck KGaA's key competitors?
Some companies that are related to Merck KGaA include Canopy Growth (WEED), Bausch Health Companies (BHC), Aurora Cannabis (ACB), Hikma Pharmaceuticals (HIK), Evotec (EVT), Aphria (APHA), Hexo (HEXO), HEXO (HEXO), Knight Therapeutics (GUD), Green Organic Dutchman (TGOD), OrganiGram (OGI), Supreme Cannabis (FIRE), HLS Therapeutics (HLS), Flowr (FLWR) and Benchmark (BMK).
What other stocks do shareholders of Merck KGaA own?
Who are Merck KGaA's key executives?
Merck KGaA's management team includes the folowing people:
- Dr. Stefan Oschmann, Chairman of Exec. Board & CEO (Age 62)
- Dr. Marcus Kuhnert, CFO & Member of Exec. Board (Age 51)
- Dr. Kai Beckmann, CEO of Performance Materials & Member of the Exec. Board (Age 54)
- Dr. Udit Batra, CEO of Life Science & Member of Exec. Board (Age 48)
- Ms. Belén Garijo López M.D., CEO of Healthcare & Member of the Exec. Board (Age 59)
What is Merck KGaA's stock price today?
One share of MRK stock can currently be purchased for approximately €104.75.
How big of a company is Merck KGaA?
What is Merck KGaA's official website?
How can I contact Merck KGaA?
The company can be reached via phone at 49 6151 72 0.
MarketBeat Community Rating for Merck KGaA (ETR MRK)
MarketBeat's community ratings are surveys of what our community members think about Merck KGaA and other stocks. Vote "Outperform" if you believe MRK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRK will underperform the S&P 500 over the long term. You may vote once every thirty days.
